Ipsen S.A. (XPAR:IPN) (France) was the Fund’s top contributor in the quarter. Ipsen is a pharmaceutical company with 75% of sales generated from specialty drugs. In the quarter, Ipsen announced that it would acquire the rights to Merrimack Pharmaceuticals’” ” pancreatic cancer treatment. In our view, this acquisition would expand Ipsen’s oncology assets, bolster its geographic reach and provide significant growth potential.
From Roger Edgley's 1st Quarter 2017 Wasatch International Growh Fund Shareholder Letter.